Host lysozyme-mediated lysis of Lactococcus lactis facilitates delivery of colitis-attenuating superoxide dismutase to inflamed colons
Abstract
Microbes hold promise as an inflammatory bowel disease (IBD) therapy. Lactococcus lactis, which has not been appreciated as a beneficial microbe, attenuated colitis in three preclinical mouse IBD models. Neither colonization nor an intact bacterium throughout the colon per se was required. Rather, host lysozyme-mediated lysis in an inflamed colon led to L. lactis's release of its superoxide dismutase, which was necessary for its colitis-attenuating and oxidative stress-reducing activity. Overall, these findings unveil a mechanism by which a bacterium offers benefits to the host but requires the host for targeted release of this beneficial activity. Furthermore, because L. lactis is generally regarded as safe, it represents an opportunity for rapid bench-to-bedside testing in IBD.
- Publication:
-
Proceedings of the National Academy of Science
- Pub Date:
- June 2015
- DOI:
- 10.1073/pnas.1501897112
- Bibcode:
- 2015PNAS..112.7803B